RESUMO
Tocilizumab is a recombinant humanized monoclonal antibody against interleukin(IL)- 6 receptor (IL - 6R). It can prevent IL - 6 from binding to membrane - bound or soluble IL - 6R,thus blocking IL - 6 mediated signal transduction,and clinically alleviating inflammation and joint destruction in rheumatoid arthritis(RA). Both in the American and European Union,intravenous Tocilizumab has been approved for the treatment of both systemic juve-nile idiopathic arthritis(sJIA)and polyarticular JIA(pJIA)in patients aged ﹥ 2 years old. The approval was based on the favorable results from 2 randomized,double - blind,placebo - controlled,multinational,phase Ⅲ trials conducted in patients aged 2 - 17 years old with active sJIA or pJIA. Tocilizumab was generally well tolerated in patients with sJIA and pJIA. The most frequently reported adverse events in Tocilizumab recipients were infections,neutropenia,impaired liver function,etc.
RESUMO
?ln recent years, the number of patients with diabetes increase rapidly. Diabetic retinopathy ( DR ) , one of the complications of diabetes, is also the important aspect of current and future prevention of blindness in our country. Now, more and more scholar have noticed the important role of immune inflammation in the pathogenesis of diabetic retinopathy. ln this article, we reviewed the role of interleukin-6 ( lL-6 ) in diabetic retinopathy.